Beneficial Ownership Report · SCHEDULE 13G/A
Tempus Al, Inc.
TEMNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Tempus Al, Inc.
- Company CIK
- 0001717115
- Street
- 600 West Chicago Avenue
- Street (continued)
- Suite 510
- City
- Chicago
- State / country code
- IL
- Postal code
- 60654
Statement details
- Amendment number
- 2
- Security class
- Class A Common Stock, par value $0.0001 per share
- Event date
- 06/18/2025
- Rule designation
- Rule 13d-1(d)
Reporting person 1
- Name
- Bradley A. Keywell
- Citizenship / organization
- X1
- Reporting person type
- IN
- Aggregate amount owned
- 6,071,744.00
- Percent of class
- 3.46
- Sole voting power
- 0.00
- Shared voting power
- 6,071,744.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 6,071,744.00
- Aggregate excludes certain shares
- N
- Comments
- Mr. Keywell holds these shares indirectly through (i) a grantor retained annuity trust (195,160 shares); (ii) The Keywell Foundation, Inc., a Delaware corporation of which he is President ("KF"). As such, he has sole voting and dispositive power of the shares held by KF; and (iii) BK TL21 LLC, a Delaware limited liability company ("BK") of which he is the sole member and manager. As such, Mr. Keywell holds shared voting and dispositive power over the shares owned by BK; and Churchill Investments 21 LLC, a Delaware limited liability company ("CI"). Mr. Keywell is the managing member of the managing member of CI and as such has shared voting and dispositive control over these shares. The percentage is based on 175,390,967 shares of the issuer's Class A Common Stock, par value $0.0001 per share, outstanding as of July 24, 2026 as reported in the issuer's Quarterly Report on Form 10-Q filed on July 30, 2026.
Reporting person 2
- Name
- BK TL21 LLC
- Citizenship / organization
- DE
- Reporting person type
- CO
- Aggregate amount owned
- 2,213,198.00
- Percent of class
- 1.26
- Sole voting power
- 2,213,198.00
- Shared voting power
- 0.00
- Sole dispositive power
- 2,213,198.00
- Shared dispositive power
- 0.00
- Aggregate excludes certain shares
- N
- Comments
- BK holds these shares directly, and as such, BK holds sole voting and dispositive power over the shares. The percentage is based on 175,390,967 shares of the issuer's Class A Common Stock, par value $0.0001 per share, outstanding as of July 24, 2026 as reported in the issuer's Quarterly Report on Form 10-Q filed on July 30, 2026.
Reporting person 3
- Name
- The Keywell Foundation Inc
- Citizenship / organization
- DE
- Reporting person type
- OO
- Aggregate amount owned
- 357,900.00
- Percent of class
- 0.02
- Sole voting power
- 357,900.00
- Shared voting power
- 0.00
- Sole dispositive power
- 357,900.00
- Shared dispositive power
- 0.00
- Aggregate excludes certain shares
- N
- Comments
- KF holds these shares directly, and Mr. Keywell as President holds sole voting and dispositive power over these shares. The percentage is based on 175,390,967 shares of the issuer's Class A Common Stock, par value $0.0001 per share, outstanding as of July 24, 2026 as reported in the issuer's Quarterly Report on Form 10-Q filed on July 30, 2026.
Reporting person 4
- Name
- Churchill Investments 21 LLC
- Citizenship / organization
- DE
- Reporting person type
- CO
- Aggregate amount owned
- 3,305,486.00
- Percent of class
- 1.88
- Sole voting power
- 3,305,486.00
- Shared voting power
- 0.00
- Sole dispositive power
- 3,305,486.00
- Shared dispositive power
- 0.00
- Aggregate excludes certain shares
- N
- Comments
- CF holds these shares directly. Mr. Keywell is the managing member of the managing member of CI and as such has shared voting and dispositive control over these shares. The percentage is based on 175,390,967 shares of the issuer's Class A Common Stock, par value $0.0001 per share, outstanding as of July 24, 2026 as reported in the issuer's Quarterly Report on Form 10-Q filed on July 30, 2026.
Item 1
Issuer
Tempus Al, Inc.
Principal executive office address
600 West Chicago Avenue, Suite 510, Chicago, IL, 60654
Item 2
Citizenship
Mr. Keywell is a US citizen, BK is a Delaware limited liability company, KF is a Delaware Corporation and CI is a Delaware limited liability company.
Filing person
Bradley A. Keywell ("Mr. Keywell"), BK TL21 LLC ("BK"), The Keywell Foundation Inc ("KF") and Churchill Investments 21 LLC ("CI") each a "Reporting Person".
Principal business or residence address
Each Reporting Person's principal business address is: 718 Thompson Lane #108-274, Nashville, TN 37204.
Item 3
Not applicable indication
Y
Item 4
Percent of class
Less than 5%
Amount beneficially owned
6,071,744 shares of Class A Common Stock, par value $0.0001.
Sole voting power
Mr. Keywell - 0.00 BK - 0.00
Shared voting power
Mr. Keywell - 6,071,744 BK - 2,213,198 KF - 357,900 CI - 3,305,486
Sole dispositive power
Mr. Keywell - 0.00 BK - 0.00
Shared dispositive power
Mr. Keywell - 6,071,744 BK - 2,213,198 KF - 357,900 CI - 3,305,486
Item 5
Not applicable indication
N
Ownership of 5% or less
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
Y
Signature 1
- Reporting person
- Bradley A. Keywell
- Signed
- /s/ Bradley A. Keywell
- Title
- Bradley A. Keywell
- Date
- 10/28/2026
Signature 2
- Reporting person
- BK TL21 LLC
- Signed
- /s/ Bradley A. Keywell
- Title
- Manager
- Date
- 10/28/2026
Signature 3
- Reporting person
- The Keywell Foundation Inc
- Signed
- /s/ Bradley A Keywell
- Title
- President
- Date
- 10/28/2026
Signature 4
- Reporting person
- Churchill Investments 21 LLC
- Signed
- 1 plus 1 Ventures LLC
- Title
- /s/ Bradley A Keywell, Manager
- Date
- 10/28/2026
Company context
Tempus is a technology company making precision medicine a reality through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of de-identified multimodal data and an intelligent operating system that makes that data accessible and actionable, Tempus connects AI, diagnostics and clinical workflows to deliver more personalized patient care and accelerate the discovery, development and delivery of better medicines. By continuously transforming data into insights, Tempus